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Abstract
 
The goal of tumor immunotherapy is to elicit immune responses against autologous tumors. It
would be highly desirable that such responses include multiple T cell clones against multiple
tumor antigens. This could be obtained using the antigen presenting capacity of dendritic cells
(DCs) and cross-priming. That is, one could load the DC with tumor lines of any human his-
tocompatibility leukocyte antigen (HLA) type to elicit T cell responses against the autologous
tumor. In this study, we show that human DCs derived from monocytes and loaded with killed
 
melanoma cells prime naive CD45RA
 
1
 
CD27
 
1
 
CD8
 
1
 
 T cells against the four shared melanoma
antigens: MAGE-3, gp100, tyrosinase, and MART-1. HLA-A201
 
1
 
 naive T cells primed by
DCs loaded with HLA-A201
 
2 
 
melanoma cells are able to kill several HLA-A201
 
1
 
 melanoma
targets. Cytotoxic T lymphocyte priming towards melanoma antigens is also obtained with
cells from metastatic melanoma patients. This demonstration of cross-priming against shared
tumor antigens builds the basis for using allogeneic tumor cell lines to deliver tumor antigens to
DCs for vaccination protocols.
Key words: shared tumor antigens • cross-priming • tumor immunity • tumor vaccine • 
immunotherapy
 
Introduction
 
The induction of tumor immunity is a multistep process
that includes: (a) the capture and processing of tumor Ags
by APCs; (b) selection and differentiation of antigen-spe-
cific T cells; and (c) homing of effector lymphocytes to the
tumor site where recognition of restriction elements leads
to tumor elimination (for reviews, see references 1–3).
 
Many tumors show some antigenicity, and known tu-
 
mor-associated Ags (TAAs)
 
1
 
 include nonmutated, overex-
pressed, or inappropriately expressed tissue differentiation
Ags (4–6). However, only a few tumors are associated with
effective immune responses (1–3, 7, 8). In this context,
dendritic cells (DCs) represent attractive vectors for tumor
immunotherapy because of their unique properties, high
Ag capture and presenting capacity, which result in ex-
tremely efficient induction and maintenance of immune
responses (3, 9–11). Whereas several strategies to deliver
TAAs to DCs have been successfully employed to induce
TAA-specific immune responses both in vitro and in ani-
mal models (12–18), optimal antigen loading strategies for
human trials still remain to be determined. The most com-
monly used, clinically approved approach is based on load-
ing empty MHC class I molecules with exogenous pep-
tides. However, this is limited by: (a) peptide restriction to
a given HLA type; (b) induction of CTL responses only;
and (c) limitation of the induced responses to defined
TAAs. These TAAs have been identified based on the T
cell responses in individual tumor-bearing patients, which
raises the question as to whether or not they represent true
tumor rejection Ags. Indeed, if judged by the rate and du-
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rability of tumor clearance, many immunotherapy proto-
cols in human cancer have shown limited efficacy (19, 20),
justifying research for improved strategies.
Recent studies demonstrate that DCs capture killed tu-
mor cells overexpressing defined TAAs and present these
TAAs to elicit recall CTL responses (21, 22). Such an ap-
proach offers new possibilities for TAA delivery to DCs
because the use of tumor cells as a source of Ags should
provide: (a) both MHC class I and class II epitopes leading
to a diverse immune response involving many clones of
CTLs and CD4 T cells, the latter being able to recruit
other effectors such as macrophages and eosinophils (1, 23);
(b) a broad spectrum of presented TAAs resulting in a
broader repertoire of elicited T cell responses; and (c) stable
and durable expression of peptide–MHC complexes suffi-
cient for the priming of naive T cells (24–26).
We have explored whether loading DCs with killed al-
logeneic tumor cells, without manipulation of TAA ex-
pression, would permit T cell priming and selection of T
cells specific for shared TAAs. Melanoma was used as a tu-
mor model because numerous shared TAAs have been
identified, possibly including tumor rejection Ags as sug-
gested by tumor regression in animal models and some hu-
man trials (27, 28). In this study, we demonstrate that DCs
loaded with killed allogeneic melanoma cells prime naive T
cells to differentiate into CTLs that are specific for a broad
spectrum of shared melanoma Ags and are able to kill mel-
anoma cell lines. This demonstration of cross-priming
against shared tumor Ags builds the basis for using alloge-
neic tumor cell lines to deliver tumor Ags to DCs for vac-
cination protocols.
 
Materials and Methods
 
Media and Reagents.
 
Complete culture medium (CM) con-
sisted of RPMI 1640, 1% 
 
l
 
-glutamine, 1% penicillin/streptomy-
cin, 50 mM 2-mercaptoethanol, 1% sodium pyruvate, 1% essen-
tial amino acids, and 10% heat-inactivated FCS (GIBCO BRL).
For T cell cultures, FCS was replaced by 10% human serum AB
(Gemini Bio-Products). GM-CSF (Schering-Plough or Immu-
nex), soluble CD40 ligand (CD40L; Immunex), and IL-7 (Immu-
nex or R&D Systems) were used at the respective concentrations
of 100 ng/ml, 200 ng/ml, and 10 IU/ml. IL-4 (Schering-Plough
or R&D Systems) was used at 5 ng/ml and IL-2 (Genzyme) was
used at 10 IU/ml. Betulinic acid (BA) (Sigma-Aldrich) was used
at the concentration of 10 mg/ml.
 
Synthetic Peptides.
 
Melan/MART-1
 
27–35
 
 (AAGIGILTV),
gp100
 
g209-2M
 
 (IMDQVPFSV), tyrosinase
 
368–376
 
 (YMDGTM-
SQV), MAGE-3
 
271–279
 
 (FLWGPRALV), and PSA1
 
141–150
 
 (FLTP-
KKLQCV) were 
 
.
 
70% pure as indicated by HPLC analysis (Bio-
Synthesis). Lyophilized peptides were dissolved in DMSO,
diluted to 1 mg/ml in apyrogen water, and stored at 
 
2
 
80
 
8
 
C.
 
Cell Lines. 
 
The Colo829 and SkMel28 melanoma cell lines,
K562, LnCAP prostate carcinoma cell line, 1806 breast cancer
cell line (established by Drs. A. Gazdar and J. Minna at Univer-
sity of Texas Southwestern Medical Center, Dallas, TX), and T2
cells were from the American Type Culture Collection. The
Me275 and Me290 cell lines were established at the Ludwig
Cancer Institute in Lausanne. All cell lines were maintained
in CM.
 
Induction of Tumor Cell Death.
 
ME275 cell death was in-
duced by treatment with 10 
 
m
 
g/ml of BA for 48 h. Colo829 cells
were killed by the same method, or by 
 
g
 
-irradiation (150 Gy and
then cultured for 48 h in serum-free medium). Cell death was as-
sessed by morphology, externalization of phosphatidylserine us-
ing FITC-labeled annexin V (Caltag), and staining with DNA-
specific dyes, 7AAD and trypan blue (Sigma-Aldrich).
 
Generation of Monocyte-derived DCs.
 
Immature DCs were
generated either from Ficoll-separated PBMCs of HLA-A201
 
1
 
healthy volunteers (Institutional Review Board 097-053) or from
patients with stage IV melanoma (enrolled in an unrelated DC
vaccination clinical trial, Institutional Review Board 097-053).
PBMCs from nonmobilized or G-CSF (Amgen) mobilized blood
were suspended in CM and allowed to adhere onto plastic dishes
(Falcon 6-well) for 2 h at 37
 
8
 
C. The nonadherent cells were re-
moved, and the adherent cells were cultured in CM for 6 d. GM-
CSF and IL-4 were added in the culture every 2 d, and the DC
recovery at day 7 as determined by immunofluorescence and
FACS
 
®
 
 analysis was 
 
.
 
90% of CD1a
 
1
 
 cells. To induce DC matu-
ration, soluble CD40L was added in the culture from day 5 to
day 7. CD40L can be replaced by Poly I:C to induce DC matu-
ration (data not shown).
 
T Cell Purification.
 
Purified CD4
 
1
 
 and CD8
 
1
 
 T cells (au-
tologous to the DCs) were depleted of other cells using purified
CD4 (13B8.2), CD8 (B9.11), CD14 (RM052), CD16 (3G8),
CD19 (J4,119), anti-CD45RO (UCHL1), CD56 (NKH-1),
anti–HLA-DR (B8.12.2), anti-glycophorin A (D2.10), mAbs
(Immunotech), and goat anti–mouse IgG Dynabeads (Dynal).
For CD8
 
1
 
CD45RA
 
1
 
CD27
 
1
 
 T cells, the CD8
 
1
 
 T cells were
stained with both anti-CD45RA–PE and anti-CD27–FITC
(Becton Dickinson) and were FACS
 
®
 
 sorted.
 
Flow Cytometry Analysis.
 
FACS
 
®
 
 analysis was performed
on a FACSCalibur™ and sorting was done on a FACS Van-
tage™ (Becton Dickinson). Antibodies used to phenotype or sort
the cells were anti-CD1a–FITC labelled (Biosource Interna-
tional), anti-CD14–APC, anti-CD80–PE, anti-CD83–PE, anti-
CD86–PE, anti–HLA-DR–PerCP, anti-CD45RA–PE, and anti-
CD27–FITC.
 
Confocal Analysis.
 
Living cells were allowed to adhere on
polylysine-coated slides (Baxter) for 30 min at room temperature
and supernatant was then removed. After fixation for 10 min with
4% paraformaldehyde in PBS, cells were washed with 0.1% gly-
cine in PBS, then permeabilized with 0.1% Triton (Sigma-
Aldrich) in PBS. After a wash in PBS/0.5% saponin/0.2% BSA/
0.2% gelatin, slides were incubated for 30 min at room tempera-
ture with the NKI/beteb anti-gp100 antibody (Biodesign) fol-
lowed by Texas red–conjugated anti–mouse Ab, washed, incu-
bated with 10% mouse serum followed by biotinylated Melan
A/MART-1 antibody (A103; a gift from Dr. E. Stockert, Ludwig
Institute for Cancer Research at
 
 
 
New York, NY), and revealed
with FITC-conjugated streptavidin. For double gp100/HLA-DR
stainings, loaded or unloaded DCs were labelled with NKI/beteb
following the same protocol, and then incubated for 30 min with
an anti–HLA-DR, FITC-conjugated antibody after 10 min neu-
tralizing incubation with mouse serum. Confocal microscopy was
performed using a Leica TCS-NT SP equipped with argon, kryp-
ton, and helium/neon lasers, and a spectrophotometer was used
to separate the detection channels of FITC (510–550 nm) and
Texas red (580–660 nm).
 
T Cell Proliferation Assay.
 
CD1a, FITC-labeled DCs were
cocultured for 1 h at 37
 
8
 
C with tumor bodies, and then were
sorted based on CD1a expression (purity 
 
.
 
95%), and plated in
U-bottomed 96-well plates at graded doses. Purified CD4
 
1
 
 T
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cells or purified CD8
 
1
 
 T cells (10
 
5
 
/well/200 
 
m
 
l) were added to
the plates. The proliferation assay was carried out in CM supple-
mented with heat-inactivated 10% human AB serum. Soluble
CD40L (200 ng/ml) was added to induce DC maturation and IL-2
(10 U/ml) to support the proliferation of purified CD8
 
1
 
 T cells.
After 5 d, tritiated thymidine (NEN Life Science Products) was
added at the activity of 1 
 
m
 
Ci/well. The plates were harvested 16 h
later (Wallac) and incorporated radioactivity was measured.
 
Generation of Specific CTLs.
 
DCs loaded with tumor-derived
cell bodies and sorted were used as stimulatory cells while autolo-
gous purified CD8
 
1
 
 T cells, CD8
 
1
 
CD45RA
 
1
 
CD45RO
 
2
 
, or
CD8
 
1
 
CDR45A
 
1
 
CD27
 
1
 
 T cells were used as responders. Cul-
tures were prepared in 24-well plates (Costar) by plating loaded
DCs at
 
 
 
10
 
5
 
 cells with 10
 
6
 
 T cells in a final volume of 1 ml. CM
was supplemented with 10% AB serum, soluble CD40L, IL-7 (10
IU/ml week 1), and IL-2 (10 IU/ml in weeks 2 and 3). T cells
were restimulated weekly for an additional 2 wk with loaded or
unloaded DCs. 6 d after the last stimulation, cells were harvested
and their cytotoxic activity as well as the capacity for IFN-
 
g
 
 re-
lease was tested.
 
51
 
Cr Cytotoxicity Assay.
 
Cytotoxicity was measured in a
standard 4-h 
 
51
 
Cr-release assay. In brief, T2 cells were pulsed
overnight with 10 
 
m
 
g/ml of the various peptides. Then, the dif-
ferent targets were labeled with 
 
51
 
Cr (NEN Life Science Prod-
ucts) and washed three times with PBS. CTLs were cocultured at
37
 
8
 
C for 4 h with 10
 
3
 
 
 
51
 
Cr-labeled target cells in 200 
 
m
 
l of CM
supplemented with 10% AB serum in 96-well culture plates. Af-
ter 4 h, 50 
 
m
 
l of supernatant was collected and the percentage of
killed cells was calculated using the formula: % release 
 
5 
 
100 
 
3
 
(cpm experiment 
 
2
 
 cpm
 
 
 
spontaneous release)/(cpm maximum
release 
 
2 
 
cpm spontaneous release).
 
Enzyme-linked Immunospot Assay for IFN-
 
g 
 
Release.
 
To
quantitate antigen-specific, IFN-
 
g
 
–releasing effector T cells, an
enzyme-linked immunospot (ELISPOT) assay was used as rec-
ommended by the Mabtech. CD8
 
1
 
 T cells (1–2 
 
3
 
 10
 
5
 
 per well)
were added in triplicate to nitrocellulose-bottomed 96-well plates
(MAHA S4510; Millipore) precoated with the primary anti–IFN-
 
g
 
mAb (1-D1K; Mabtech) in 50 
 
m
 
l cRPMI per well. For the de-
tection of specific reactive T cells, autologous mature monocyte-
derived DCs pulsed with MHC class I–restricted peptides were
added at 10
 
4
 
 per well (final volume 100 
 
m
 
l/well). After 20 h,
wells were washed six times and incubated with biotinylated sec-
ond mAb to IFN-
 
g
 
 (7 B6-1; Mabtech) for 2 h, washed again, and
stained with Vectastain Elite kit (Vector Laboratories).
 
Results
 
Melanoma Cell Lines as a Source of Ags.
 
To determine
whether killed allogeneic melanoma cells delivered to DCs
would permit selection and expansion of T cells specific for
shared melanoma Ags, we identified two melanoma cell
lines, Me275 and Colo829. The choice was based on: (a)
the expression of HLA-A201 by Me275 cells but not by
Colo829 cells, and (b) the expression of “known” mela-
noma TAAs, both cell lines expressing Melan A/MART-1,
gp100, tyrosinase, and MAGE-3 at the RNA and protein
level (Fig. 1 A) (29; data not shown).
To generate killed tumor cells, several death-inducing
factors were tested including DNA damage and receptor-
mediated death, with cell death monitored using the an-
nexin V/propidium iodide staining. Colo829 cells could be
Figure 1. Immature DCs capture killed melanoma cells. (A) Colo829 cells are labelled with mAbs specific for gp100 (red) and Melan A/MART-1
(green). Confocal analysis shows that TAAs are expressed in different vesicular compartments. (B–D) DCs are cultured for 1 h with killed Colo829 cells
and sorted according to size and granularity (forward/side scatter), fixed, and labelled with anti-gp100 (red) and anti–HLA-DR (green). Confocal micros-
copy analysis shows gp100 staining in the cytoplasm of most HLA-DR1 cells. (B) Projection of four xy serial sections. (C) Insert of a single section; orig-
inal magnification: 32.5. (D) xz vertical serial sections (1–3) and sum of gp100 staining of one cell (4). Representative of several experiments with
Colo829 and Me275 cells. Bars, 10 mm.
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killed by 
 
g
 
-irradiation serum starvation (150 Gy, 
 
.
 
30% of
dead cells). Me275 cells proved resistant to 
 
g
 
-irradiation as
well as receptor-mediated death via either Fas ligation,
TNF, or TNF-related apoptosis-inducing ligand (TRAIL)
(not shown). However, Me275 cells undergo swift death
when treated with BA (30–32). BA is particularly active
against melanoma (as well as malignant brain tumor cells)
and induces mitochondria-dependent death through the
activation of caspase-8 and caspase-3. Based on initial ki-
netic and dose–response experiments (not shown), mela-
noma cells were treated for 48 h with 10 
 
m
 
g/ml BA
(
 
.
 
50% dead cells, a combination of apoptosis and necrosis).
Because both Colo829 and Me275 grow as adherent cells
and detach when dying, we used the nonadherent fraction
composed mostly of killed cells for DC loading.
 
DCs Capture Killed Melanoma Cells and Present Their Ags
to Autologous T Cells.
 
We first determined the capacity of
immature monocyte-derived DCs to capture killed mela-
noma cells. To this end, immature DCs were mixed with
killed melanoma cells at a 1:5 ratio and incubated for 1 h at
37
 
8
 
C to allow phagocytosis (conditions were established as
optimal in preliminary experiments). Thereafter, DCs were
sorted based on forward scatter/side scatter properties re-
flecting size and granularity. The presence of gp100 mela-
noma protein within the HLA-DR–labelled DC was de-
termined after subsequent staining with a specific mAb.
Confocal microscopy analysis revealed that .90% of DCs
internalized the gp100-labelled melanoma cells (Fig. 1,
B–D). The Melan A/MART-1 epitope recognized with
the A103 antibody was lost.
The presentation of Ags captured by DCs was assessed
by their ability to induce the proliferation of autologous T
cells. CD1a-labelled immature DCs were loaded with
killed melanoma cells, sorted based on CD1a expression
(.90% purity), and cocultured with purified (.90%) au-
tologous T cells in the presence of CD40L, which induces
maturation of both loaded and unloaded DCs as deter-
mined by CD83 expression (not shown). The T cells pro-
liferated when cultured with DCs loaded with killed
Me275 cells (but not when cultured with killed melanoma
cells only) (Fig. 2).
These results demonstrate that DCs capture killed alloge-
neic melanoma cells and present their Ags, whether alloan-
tigens or melanoma-associated Ags, to autologous T cells.
DCs Loaded with Killed Melanoma Cells Elicit CTLs Able to
Kill Melanoma Cells. We next determined whether DCs
loaded with killed melanoma cells elicit T cells with cyto-
toxic activity against the melanoma cells used for immuni-
zation. The immature HLA-A2011 DCs were loaded with
killed Me275, sorted, and used to stimulate purified autolo-
gous CD81 T cells over a 3-wk culture. Soluble CD40L
was added to induce DC maturation, as well as IL-7 (10
U/ml week 1) and IL-2 (10 U/ml in weeks 2 and 3) to
help T cell proliferation. The T cells were harvested after
Figure 2. DCs loaded with killed melanoma cells induce
T cell proliferation. (a) Unloaded DCs (UL-DC) and
loaded DCs (L-DC) are sorted and cultured with purified
autologous CD41 and (b) CD81 T cells (with CD40L and
IL-2). Thymidine incorporation at day 5. Representative
of two experiments.
Figure 3. Induction of CTLs by DCs
loaded with killed melanoma cells. Purified
CD81 T cells are cultured for 3 wk with
unloaded DCs (UL-DC) or DCs loaded
with Me275 (L-DC). (a) T cells are tested in
a 4-h chromium-release assay, using as tar-
gets immunizing Me275 cells and K562
cells as a control for NK activity (mean 6
SE, n 5 4), as well as (b) unrelated HLA-
A2011 tumor cell lines, prostate cancer (Ln-
Cap) and breast cancer (1806). No CTLs
are elicited when T cells are cultured with
killed melanoma cells without the DCs (not
shown).
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three stimulation cycles and their cytotoxic activity was de-
termined using Me275, unrelated HLA-A2011 tumor cells,
and K562. As shown in Fig. 3, loaded DCs induced differ-
entiation of CTLs able to kill the Me275 melanoma cells, at
50 6 10% specific lysis (mean 6 SE, n 5 4; 6 6 0.5% spe-
cific lysis using control T cells cultured with unloaded
DCs), but not the unrelated HLA-A2011 LnCAP or 1806
cells or the NK-sensitive K562 cell line.
These results demonstrate that DCs loaded with killed
allogeneic melanoma cells can trigger CD81 T cells to dif-
ferentiate into CTLs able to kill the melanoma cells used
for immunization.
Loading of DCs with Killed Allogeneic Melanoma Cells In-
duces CTLs Specific for Multiple Shared Melanoma TAAs.
Two assays were developed to establish whether the T cell
lines generated with killed melanoma cell–loaded DCs
contained T cells specific for melanoma-associated Ags: an
overnight IFN-g ELISPOT assay with the HLA-A2011
DCs pulsed with melanoma peptides Melan A/MART-
127–35, tyrosinase368–376, MAGE-3271–279, and mutated
gp100g209-2M; and a cytotoxic chromium-release assay using
T2 cells pulsed with the four peptides as target cells. As
shown in Fig. 4 a, 3-wk CTL lines elicited using DCs
loaded with killed Me275 cells contain cells recognizing a
combination of the four melanoma peptides: 27 6 2.9 mel-
anoma-specific spots/2 3 105 T cells (mean 6 SE, n 5 3,
P 5 0.03). T cell lines generated with unloaded DCs and
peptide-pulsed DCs alone (without the T cells) yielded 3 6
1 and 4 6 1.5 spots, respectively. As shown in Fig. 4 b,
these T cell lines are able to kill T2 cells pulsed with a
combination of the four peptides (56 6 13% specific lysis;
mean 6 SE, n 5 3), but not T2 cells loaded with a pros-
tate-specific antigen–derived peptide, thus indicating speci-
ficity for melanoma TAAs. The ability to induce mela-
noma-specific CTLs was not restricted to Me275 cells, as
the T cells elicited by DCs loaded with the HLA-A2012
Colo829 also contained cells that could kill the T2 cells
loaded with each of the four melanoma peptides (Table I).
Thus, different melanoma cell lines and different meth-
ods to kill melanoma cells can be used to load DCs to elicit
CTL lines specific for melanoma-associated Ags.
DCs Loaded with Killed Melanoma Cells Prime Naive CD8
T Cells to Differentiate into Melanoma-Specific CTLs. We
wondered whether induction of melanoma-specific
CTLs was due to priming of naive T cells. First,
CD45RA1CD45RO2 naive CD81 T cells (.80% pure)
were cultured with DCs loaded with killed Me275 cells. In
two independent experiments, the elicited T cells were
able to kill: (a) T2 cells pulsed with the four melanoma
peptides (up to 70% specific lysis, Fig. 5 A); (b) T2 cells
Figure 4. Induction of melanoma-specific CTLs
by killed melanoma cell–loaded DCs. Purified
CD81 T cells are cultured for 3 wk with unloaded
(UL-DC) or Me275-loaded DCs (L-DC). (a) IFN-g
ELISPOT using as targets DCs, either unpulsed or
pulsed with the four melanoma peptides (4P). Rep-
resentative experiment from three performed using
DCs and T cells from different donors. (b) CTL ac-
tivity in a 4-h chromium-release assay using un-
pulsed and melanoma peptide–pulsed (4P; mean
values of three experiments) and control peptide
PSA-pulsed T2 cells (one experiment).
Table I. T Cells Elicited by Killed Melanoma Cell–loaded DCs Kill Melanoma Peptide–pulsed T2 Cells
No peptide Tyrosinase gp100 MAGE-3 MART-1
Exp. 1/Me275 18 6 5* 68 6 5 48 6 4 ND ND
Exp. 2/Me275 22 6 2.5 60 6 7 40 6 9.5 ND ND
Exp. 3/Colo829 19 6 4.5 65 6 9.5‡ 34 6 3.5‡ 33 6 3‡ 36 6 7.5‡
Mean 6 SD 20 6 2 64 6 4 41 6 7
P 5 0.006 P 5 0.03
Percent specific lysis, expressed as mean of triplicates 6 SD. Paired two-tailed t test on log transformed data comparing the killing of unpulsed and
peptide-pulsed T2 cells. Exp., experiment.
*23% lysis using PSA peptide–loaded T2 cells.
‡P 5 0.02.
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loaded with a single peptide, either tyrosinase, gp100, or
MAGE-3 (Fig. 5 a); and (c) the Me275 cell line used for
immunization (not shown).
Though mostly comprised of truly naive T cells, the
pool of CD81CD45RA1CD45RO2 T cells contains a
small fraction of “effector memory” cells that might expand
in our culture conditions. Therefore, based on CD27
expression, the pool of CD81CD45RA1CD45RO2 T
cells was subdivided to distinguish truly inexperienced T cells
(CD45RA1CD271) from uncommitted effector T cells
(CD45RA1CD272) (33). When cultured with killed mel-
anoma cell–loaded DCs, these CD81CD45RA1CD271 T
cells yielded melanoma-specific CTLs able to kill both the
melanoma cells used for immunization (up to 75% specific
lysis, Fig. 5 b) and T2 cells pulsed with melanoma peptides
(75% melanoma peptide–specific killing, Fig. 5 c). The in-
duction of melanoma-specific T cells was further con-
firmed by IFN-g ELISPOT with melanoma peptide–
pulsed, autologous DCs (23 peptide-specific spots/105 T
cells versus 5 spots/105 T cells background, not shown).
Most importantly, these naive T cells primed by DCs
loaded with HLA-A2012 Colo829 cells were able to kill
HLA-A2011 melanoma targets including Me275, Me290,
and SkMel28 cells, thus demonstrating cross-priming
(Fig. 6).
Taken together, our results demonstrate for the first time
that DCs loaded with killed allogeneic melanoma cells can
prime naive CD81 T cells to differentiate into CTLs spe-
cific for shared melanoma-associated Ags and are able to
kill tumor cells HLA matched to the DCs.
DCs Loaded with Killed Melanoma Cells Elicit Melanoma-
specific Responses from Blood T Cells of Patients with Stage IV
Melanoma. The main thrust behind the above experi-
ments is the prospect of vaccinating melanoma patients
with DCs loaded with killed melanoma cells. However,
these patients may suffer from immune dysfunction that
Figure 5. DCs loaded with killed
melanoma cells prime naive T cells.
Naive CD81CD45RA1CD45RO2
T cells are cultured for 3 wk with
unloaded DCs (UL-DC) or with
DCs loaded with killed melanoma
cells (L-DC). T cells are tested in a
4-h chromium-release assay. (a)
CTLs elicited by DCs loaded with
Me275 bodies kill the T2 cells
pulsed with different melanoma
peptides (paired two-tailed t test on
log transformed data comparing the
killing of unpulsed and peptide-
pulsed T2 cells). (b) Naive CD271
CD45RA1CD81 T cells differenti-
ate into CTLs able to kill the cell
line used for immunization, and (c)
T2 cells pulsed with melanoma pep-
tides (4P) but not PSA peptide (rep-
resentative of two experiments).
Figure 6. Cross-priming using DCs loaded with
killed melanoma cells. Naive CD271CD45RA1CD81
T cells are primed by autologous HLA-A2011 DCs
loaded with killed HLA-A2012 Colo829 cells. The
elicited T cells are able to kill HLA-A2011 melanoma
targets but not HLA-A2011 breast cancer cells or au-
tologous monocytes.
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may be reflected in the inability of their blood T cells to
mount melanoma-specific immune responses (34). There-
fore, we analyzed whether or not CD81 T cells from pa-
tients with metastatic melanoma could be differentiated
into effective melanoma-specific CTLs. Purified CD81 T
cells cultured for 3 wk with DCs loaded with killed Me275
cells contained melanoma-specific T cells as determined by
IFN-g ELISPOT using peptide-pulsed DCs (15 spots/2 3
105 T cells; Fig. 7 a, patient 6). As shown in Fig. 6 b, puri-
fied CD81 T cells cultured with killed Me275-loaded DCs
generated CTL lines able to kill Me275 cells, either un-
pulsed (50% specific lysis) or pulsed with the four mela-
noma peptides (88% specific lysis; Fig. 7 a, patient 1). In
two patients, CD45RA1CD45RO2CD81 T cells cultured
for 3 wk with killed melanoma cell–loaded DCs were
found to differentiate into melanoma-specific CTLs, as
shown by their capacity to kill T2 cells pulsed with a com-
bination of four melanoma peptides (Fig. 7, and data not
shown).
These results demonstrate that the DCs loaded with
killed allogeneic melanoma cell lines can elicit melanoma-
specific CTLs using blood T cells and DCs from patients
with advanced malignant melanoma.
Discussion
This study is the first demonstration that DCs loaded
with killed allogeneic tumor cells can prime naive CD81 T
cells to differentiate into CTLs specific for shared tumor
Ags. Indeed, melanoma-specific responses can be elicited
from truly inexperienced CD45RA1CD271CD81 T cells
(33) in a cross-priming setup. HLA-A2011 T cells primed
by autologous DCs loaded with HLA-A2012 Colo829 cells
are able to kill several HLA-A2011 melanoma targets. Im-
portantly, this approach can be used to elicit melanoma-
specific CTLs from the blood of patients with stage IV
melanoma.
Our results complement and extend recent reports on
killed tumor cells that can be provided to DCs for presenta-
tion to peptide-specific T cell lines and can detect recall re-
sponses in tumor-bearing patients (21, 22). In this study,
we show that shared TAAs do not need to be transfected
for the loaded DCs to induce TAA-specific responses. In-
deed, the melanoma model, where numerous TAAs have
been identified, indicates that DCs loaded with killed mel-
anoma cells induce: (a) T cells with CTL activity against
melanoma cell lines used for immunization, and (b) CTLs
that are specific for multiple melanoma Ags, including
epitopes of Melan A/MART-1, gp100, tyrosinase, and
MAGE-3, as demonstrated in the T2 killing and ELISPOT
assays. The implications of these findings are the possibility
of inducing responses against multiple tumor Ags (this may
permit minimization of tumor escape by loss of a given an-
tigen expression), and the opportunity to identify novel tu-
mor Ags relevant for tumor rejection (2).
A possible explanation for the induced melanoma pep-
tide–specific CTL responses is that peptides are actually
formed by the melanoma cells and just transferred to DCs.
However, the generation of melanoma TAA-specific
HLA-A201–restricted CTLs using the killed HLA-A2012
Colo829 cell line suggests antigen processing rather than
peptide transfer. Identification of T cells reactive with the
MAGE-3271–279 epitope, which is not expressed by mela-
noma cells because it cannot be generated by a standard
proteasome (35), further suggests antigen processing. How-
ever, we cannot formally exclude the possibility that killed
Figure 7. DCs loaded with killed melanoma cells stimu-
late melanoma-specific CD81 T cells from the blood of pa-
tients with metastatic melanoma. Purified CD81 T cells
are cultured for 3 wk with unloaded (UL-DC) or Me275-
loaded DCs (L-DC). (a) IFN-g ELISPOT using DCs, ei-
ther unpulsed or pulsed with four melanoma peptides (4P).
Results from one patient. (b) T cells are able to kill Me275
used for immunization, and the killing is increased when
Me275 cells are pulsed with the four melanoma peptides.
Similar results were obtained in two patients. (c)
CD81CD45RA1CD45RO2 T cells cultured for 3 wk
with DCs loaded with killed Me275 cells, kill T2 cells
pulsed with four melanoma peptides.
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melanoma cells may display immunoproteasome-like enzy-
matic activity that could result in the generation of the
MAGE-3271–279 epitope.
The range of melanoma TAA specificities reported in
this study is likely to be underestimated because we have
used peptides representing only four melanoma epitopes
and restricted to a given HLA allele (HLA-A201). Thus,
the real repertoire of melanoma-specific responses may in
fact be much higher as it is likely to incorporate (a) other
epitopes presented by other HLA alleles; (b) other defined
tumor Ags expressed in melanoma cells such as tyrosinase-
related protein 2, her2/neu, and potentially TERT (36–
38); and (c) “unknown,” i.e., unidentified melanoma
TAAs. This may explain the apparent discrepancy between
the high killing of melanoma targets and relatively low fre-
quency of T cells specific for the four melanoma peptides
in the ELISPOT assay.
There is no consensus as to whether shared tumor Ags or
unique tumor-specific Ags would provide the optimal basis
for immunotherapy protocols. The current approach based
on the use of allogeneic tumor cell lines to induce re-
sponses against shared TAAs presents numerous advantages:
(a) these relatively well-characterized antigen sources can
permit a more rigorous clinical assessment of responses to
DC vaccines than the ill-defined autologous tumor prepa-
rations that cannot permit standardization and are often
limiting in their quantity; (b) applicability to many patients
regardless of HLA type; (c) the possibility of identifying
novel, shared tumor Ags that may “escape” detection using
autologous tumors due to potential immunodominance of
unique tumor Ags; and (d) the possibility of mounting tu-
mor-specific CD4 responses, the importance of which has
been demonstrated in mouse tumor models, in the devel-
opment of tumor immunity (1, 23). In this context, we are
currently analyzing the specificity of induced CD4 T cells.
In conclusion, our study demonstrates that DCs loaded
with killed allogeneic melanoma cells can cross-prime
CTLs specific for multiple melanoma Ags.
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